PTO

  • September 12, 2011
    Guest Post

    By Marla Grossman, Partner, American Continental Group


    Last week, the Congress passed the most comprehensive patent reform in the U.S. in over 50 years. Just hours before President Obama gave his jobs speech, the U.S. Senate passed H.R. 1249 by a vote of 89 to 9, clearing the bill for the president’s signature. The bill’s title is the Leahy-Smith America Invents Act, and it will help promote American innovation, thereby creating additional jobs in this country and, hopefully, enhance the economy. 

    Passage of the America Invents Act is the culmination of more than a decade of efforts of innovators and public policy makers. Several of the provisions implement recommendations made by the Federal Trade Commission in 2003 and the National Academy of Sciences in 2004. Congress worked on this bill from the 108th – 112th congressional sessions, holding dozens of hearings and engaging in extensive debate.

    Some of the key features of the final legislation include:

    • Transitioning to a first-inventor-to-file system, harmonizing the U.S. patent system with the rest of the world;
    • Replacing the costly interference proceedings with derivation proceedings to determine the right to a patent;
    • Updating and improving the inventor’s oath/declaration;
    • Authorizing pre-issuance submissions by third parties prior to the grant of a patent to aid patent examiners and improve patent quality;
    • Creation of a new, first-window post-grant review process to improve patent quality;
    • Improving the current inter partes system by heightening the threshold for instituting a review, making it more difficult to use the process to harass a patent owner;
    • Creation of a new supplemental examination proceeding to incentivize patent owners to commercialize their inventions despite potential flaws in the application process;
    • Making failure to disclose the best mode no longer a basis for invalidity;
    • Eliminating harassing false marking lawsuits, and addressing recent holdings that the current statute is unconstitutional; and
    • Providing for a 15 percent increase in Patent and Trademark Office (PTO) fees that will take effect 10 days after enactment of the bill so the agency can have a quick infusion of desperately needed resources.

    It is not a perfect bill. Most notably, it does not guarantee the PTO stable, future funding and does not require that the agency be able to utilize all of its user fee collections. By definition, however, a “perfect” bill is one that has no chance of ever becoming law in this country of diverse opinion and representational government.

  • May 21, 2009
    Guest Post

    By Selene Kaye, Advocacy Coordinator for the ACLU Women's Rights Project and Sandra Park, Staff Attorney for the ACLU Women's Rights Project and one of the attorneys handling this case

    Last week the ACLU and the Public Patent Foundation filed a lawsuit challenging the U.S. government's practice of granting patents on human genes - specifically, the BRCA1 and BRCA2 genes, which are associated with breast and ovarian cancer. In the last 20 or so years the U.S. Patent and Trademark Office (PTO) has issued patents on thousands of human genes - the segments of DNA that we all have in our cells - giving private corporations, individuals, and universities the exclusive rights to those genetic sequences and their usage.

    The patents on the BRCA genes are particularly broad and offensive. The PTO has granted Myriad Genetics, a private biotechnology company based in Utah, patents on both the BRCA1 and BRCA2 genetic sequences, on any mutations along those genes, on any methods for locating mutations on the genes, without further specification on the type of methods, and on correlations between genetic mutations and susceptibility to breast and ovarian cancer.